Quantcast
Home » News
Home » News

Pfizer, 23andMe team up to examine bowel disease

Published August 12, 2014 9:49 am

Research • Pharmaceutical and DNA testing companies to study its genetic underpinnings.
This is an archived article that was published on sltrib.com in 2014, and information in the article may be outdated. It is provided only for personal research purposes and may not be reprinted.

Washington • Pfizer Inc. is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Under the partnership, 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include Crohn's disease and ulcerative colitis. Patients will submit saliva samples using 23andMe's at-home collection kit and then fill out online questionnaires about their disease and symptoms.

The companies say they hope to identify genetic similarities among patients with inflammatory bowel disease, which could guide development of targeted drugs to treat the disease.



The cause of inflammatory bowel disorders is unknown, though many scientists suspect genetics play a role. Other scientists believe the diseases are triggered by a virus or bacteria.

 

 

 

USER COMMENTS
Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
comments powered by Disqus